Lilly: earnings after development charges
Lilly guides non-GAAP EPS to $35–$36, including identified acquired-IPR&D effects. Removing those charges again would test a different measure.
Eli Lilly and Company / LLYPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Lilly Q3 2026 results and full-year outlookPublished 2026-10-29
Potential outcome market
Will Lilly 2026 non-GAAP diluted EPS exceed $35.50?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.